PP
CODX

Paloma Partners’s Co-Diagnostics CODX Stock Holding History

Paloma Partners’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-628
Closed -$116K – 1216
2022
Q1 		$116K Buy
+628
New +$130K ﹤0.01% 1548
2020
Q4 		– Sell
-1,261
Closed -$514K – 1729
2020
Q3 		$514K Sell
1,261
-143
-10% -$73.5K 0.01% 1149
2020
Q2 		$815K Buy
1,404
+624
+80% +$285K 0.01% 1005
2020
Q1 		$178K Buy
+780
New +$135K 0.01% 932

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's CODX Position: Q2 2022 in Review

Paloma Partners sold out of Co-Diagnostics (CODX) in Q2 2022, closing a stake of 628 shares — an estimated $116K sold.

Paloma Partners first reported a position in CODX in Q1 2020 and held it in 4 quarters. The position peaked at $815K in Q2 2020. 69 funds tracked by Wall St. Rank hold CODX as of Q2 2022.

  • Paloma Partners reported no remaining Co-Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Paloma Partners sold 628 Co-Diagnostics shares in Q2 2022, an estimated $116K.
  • Paloma Partners first reported a position in Co-Diagnostics in Q1 2020 and held it in 4 quarters.
  • Paloma Partners's Co-Diagnostics position peaked at $815K in Q2 2020.
  • 69 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2022.

Based on Paloma Partners's 13F filing for Q2 2022, filed 15 Aug 2022.